Skip to main content
. Author manuscript; available in PMC: 2021 Jun 14.
Published in final edited form as: Lab Invest. 2020 Dec 14;101(3):396–407. doi: 10.1038/s41374-020-00511-3

Figure 3. Comparison of digital platforms and histomorphometrist scoring.

Figure 3

a Comparison of % Ki67+ve and cPARP+ve staining across platforms and, in comparison, to histomorphometrist (HM) scoring. Vehicle and cisplatin-treated NSCLC PDEs were evaluated using the different approaches. Wilcoxon paired test shows that there was no significant difference (ns) in mean positivity identified between the histomorphometrist and any software platform.

b Passing-Bablok regression analysis. PB regression was fitted to all combinations of data obtained from Platforms 1-3 and from the histomorphometrist (HM) to test for inter-platform agreeability. Green highlights a constant difference between methods. Yellow highlights fields indicating a proportional difference between methods.